Special Issue

Repurposing and Innovation: Drug Research in Neuroprotection

Message from the Guest Editor

Neurodegenerative diseases and a range of neurological disorders remain a major challenge facing modern medicine, and there are currently few treatments that can effectively prevent or reverse neuronal damage. From a pharmacological perspective, innovative compounds are often highly specific, targeting specific molecular cascades or receptors that play a role in neuronal survival and synaptic plasticity. However, they often encounter translational barriers. In contrast, drug repurposing utilizes compounds with well-defined pharmacodynamics and pharmacokinetics, including demonstrated CNS penetration and an established safety profile.

Therefore, this Special Issue will cover two interrelated aspects of modern pharmacology: the identification and characterization of novel neuroprotective compounds, and the strategic reuse of existing drugs for neuroprotective applications. We will mainly focus on the study of innovative substances with inherent neuroprotective properties and the re-evaluation of clinically approved drugs. We welcome submissions including mechanistic studies, preclinical models, clinical observations, and pharmacological analyses.

Guest Editor

Dr. Stela Dragomanova

Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, 84 A Tsar Osvoboditel Blvd., 9002 Varna, Bulgaria

Deadline for manuscript submissions

31 May 2026



Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/246644

Current Issues in Molecular Biology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cimb@mdpi.com

mdpi.com/journal/cimb





Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

